



Strides Shasun Limited
Strides House, Bilekahalli
Bannerghatta Road,
Bangalore - 560 076, India

Tel: + 91 80 6784 0000
Fax: + 91 80 6784 0700
info@stridesshasun.com
www.stridesshasun.com

November 25, 2016

BSE Limited

Sir Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:

“Strides to acquire PediaCare from Moberg Pharma”

For your information and records.

Thanks & Regards,
For **STRIDES SHASUN LIMITED**,

BADREE KOMANDUR
GROUP CFO & CS



Press Release

Friday, November 25, 2016

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road
Bangalore – 560076

Strides to acquire PediaCare from Moberg Pharma

Brand acquisition to strengthen Consumer Health Care portfolio

Bangalore, November 25, 2016. Strides Shasun Limited today announced that its wholly owned subsidiary Strides Arcolab International Limited, UK has entered into an agreement with Moberg Pharma, Sweden to acquire the 'PediaCare' brand for a total consideration of US\$ 5 million plus inventory value at closing.

PediaCare is an established paediatric cough, cold and allergy brand with annual sales of approximately US\$ 6 Million. PediaCare will form an important part of Strides expanding consumer health care portfolio and brings with it expertise in the paediatric segment as well as a strong brand name with global potential.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 13 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u>	<u>PR Consultancy</u>
Badree Komandur, Group CFO +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com

